9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance

9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance

---

Pharmacokinetics and Pharmacodynamics (PK/PD) of Parenteral Therapies

Parenteral antimicrobial optimization depends on aligning dosing strategies with the pathogen's pharmacodynamic killing characteristics.

Primary PK/PD Indices of Antimicrobial Efficacy

1. Time-Dependent Killing ($fT > \text{MIC}$):
   • Drug Classes: Beta-lactams (penicillins, cephalosporins, carbapenems, monobactams).
   • Mechanism: The rate of bacterial killing plateaus once the free, unbound drug concentration exceeds $4\text{ to }5\times\text{MIC}$. Efficacy is determined by the percentage of the dosing interval during which free drug concentrations exceed the pathogen's minimum inhibitory concentration ($fT > \text{MIC}$). For carbapenems, optimal bactericidal efficacy requires $40\% fT > \text{MIC}$; penicillins require $50\%$; cephalosporins require $60-70\%$.
   • Compounding Translation: Maximized through continuous infusions or extended infusions (e.g., piperacillin-tazobactam $3.375\,\text{g}$ infused over 4 hours every 8 hours, or meropenem $1-2\,\text{g}$ infused over 3 hours).
2. Concentration-Dependent Killing ($C_{\max}/\text{MIC}$):
   • Drug Classes: Aminoglycosides (gentamicin, tobramycin, amikacin), fluoroquinolones, daptomycin.
   • Mechanism: Higher peak concentrations produce faster and more complete bacterial eradication, coupled with a prolonged Post-Antibiotic Effect (PAE)—persistent suppression of bacterial regrowth following drug clearance. Efficacy correlates with achieving high peak-to-MIC ratios ($C_{\max}/\text{MIC} \ge 8-10$).
3. Exposure-Dependent Killing ($\text{AUC}_{24}/\text{MIC}$):
   • Drug Classes: Vancomycin, linezolid, polymyxins, daptomycin.
   • Mechanism: Clinical efficacy correlates with cumulative 24-hour total drug exposure relative to the organism's MIC.

---

Precision Therapeutic Drug Monitoring: Vancomycin and Aminoglycosides

Vancomycin AUC-Guided Precision Dosing

For decades, vancomycin therapeutic drug monitoring relied exclusively on trough concentrations ($15-20\,\mu\text{g/mL}$) as a surrogate for serious MRSA infections (bacteremia, endocarditis, osteomyelitis, hospital-acquired pneumonia).

• The Nephrotoxicity Shift: The revised ASHP/IDSA/PIDS/SIDP consensus guidelines no longer recommend trough-only monitoring ($15-20\,\mu\text{g/mL}$). High sustained troughs lead to severe, dose-dependent acute kidney injury (AKI) through proximal tubular epithelial uptake, lysosomal swelling, and intracellular oxidative stress without providing superior clinical cure rates.
• The Modern Target Standard: Target a 24-hour Area Under the Curve to MIC ratio ($\text{AUC}_{24}/\text{MIC}$) of $400\text{ to }600\,\text{mg}\cdot\text{h/L}$ (assuming a conventional broth microdilution MIC of $1.0\,\text{mg/L}$):
  • $\text{AUC}_{24}/\text{MIC} < 400\,\text{mg}\cdot\text{h/L}$: Predicts clinical failure and development of vancomycin-intermediate Staphylococcus aureus (VISA).
  • $\text{AUC}_{24}/\text{MIC} > 600\,\text{mg}\cdot\text{h/L}$: Significant exponential rise in acute nephrotoxicity.
• Monitoring Methods: Calculated using Bayesian software modeling (estimating AUC from a single trough level) or traditional two-point first-order pharmacokinetic equations (peak drawn 1-2 hours post-infusion and trough drawn within 30 minutes prior to the next scheduled dose):

$k_e = \frac{\ln(C_{\text{peak}}) - \ln(C_{\text{trough}})}{\Delta t}$

$V_d = \frac{\text{Dose}}{t_{\text{inf}} \cdot k_e} \cdot \frac{(1 - e^{-k_e \cdot t_{\text{inf}}})}{(C_{\text{peak}} - (C_{\text{trough}} \cdot e^{-k_e \cdot t_{\text{inf}}}))}$

Aminoglycoside Extended-Interval High-Dose Dosing

Traditional multiple-daily dosing ($1-2\,\text{mg/kg}$ Q8H) has been largely replaced by Extended-Interval Dosing ($5\text{ to }7\,\text{mg/kg}$ once daily) for gentamicin and tobramycin.

• Pharmacodynamic Advantage: A massive single dose achieves a high peak ($C_{\max} = 16-24\,\mu\text{g/mL}$), ensuring $C_{\max}/\text{MIC} \ge 10$ and optimizing bactericidal kill while prolonging PAE.
• Toxicity Mitigation: Aminoglycoside nephrotoxicity occurs via receptor-mediated endocytosis (megalin and cubilin receptors) in renal proximal tubular cells. These receptors are saturable. Once-daily dosing saturates these receptors transiently, and the prolonged drug-free interval allows drug levels to fall below $< 1.0\,\mu\text{g/mL}$ (or undetectable). This clearance washout facilitates cellular efflux, protecting against acute tubular necrosis (ATN) and ototoxic sensory hair cell destruction in the inner ear.

---

Catheter-Related Bloodstream Infections (CRBSI): Molecular Pathogenesis

A Catheter-Related Bloodstream Infection (CRBSI) is a primary bloodstream infection originating from an intravascular catheter, verified by differential time to positivity (DTTP: blood culture drawn from the catheter hub turns positive at least 2 hours earlier than a simultaneous peripheral percutaneous blood culture) or quantitative catheter tip segment culture ($\ge 15\,\text{CFU}$ by Maki roll-plate technique).

                  [Intravascular Catheter Ingress Pathways]
                                     │
         ┌───────────────────────────┴───────────────────────────┐
         ▼                                                       ▼
  [EXTRALUMINAL PATHWAY]                                  [INTRALUMINAL PATHWAY]
  ├── Skin microflora at puncture site                    ├── Contamination of catheter hub,
  ├── Tracks along outer surface of catheter              │   needleless ports, or infusate
  └── Dominates SHORT-TERM lines (< 14 days)             └── Dominates LONG-TERM lines (> 14 days)
                                     │
                                     ▼
                        [MICROBIAL BIOFILM FORMATION]
                        ├── Primary: S. epidermidis, S. aureus, Candida
                        ├── Synthesis of Extracellular Polymeric Substance (EPS)
                        ├── Persister bacterial cells (quiescent metabolism)
                        └── 100x to 1,000x resistance to systemic antibiotics

The Dual Mechanisms of Catheter Colonization

1. Extraluminal Route: Cutaneous bacteria residing at the insertion site track along the exterior surface of the catheter into the venipuncture canal. This mechanism accounts for the vast majority of infections in short-term central venous lines ($< 14\,\text{days}$).
2. Intraluminal Route: Contamination of the catheter hub, needleless injection ports, or infusate during line access by healthcare workers; bacteria migrate down the internal lumen. This mechanism accounts for the majority of infections in long-term central lines ($> 14\,\text{days}$), including tunneled catheters (Hickman, Broviac), PICCs, and implanted subcutaneous ports.

Biofilm Molecular Dynamics and Resistance

Within hours of catheter insertion, host plasma proteins (fibrin, fibronectin, vitronectin, laminin) coat the synthetic polymer catheter surfaces, forming a conditioning film. Free-floating planktonic bacteria adhere to this film:

• Biofilm Architecture: Staphylococcus epidermidis (coagulase-negative staphylococcus possessing polysaccharide intercellular adhesin [PIA]), Staphylococcus aureus, Enterococcus faecalis, and Candida species (C. albicans, C. parapsilosis) proliferate into dense microcolonies. They secrete an insoluble Extracellular Polymeric Substance (EPS) matrix composed of exopolysaccharides, extracellular DNA, amyloid proteins, and lipids.
• Phenotypic Tolerance: Deep within the mature biofilm matrix, bacterial cells transition into a dormant, non-dividing "persister" metabolic state. The polyanionic matrix impedes antibiotic diffusion, while the persister state renders the bacteria insensitive to cell-wall active beta-lactams and glycopeptides. Microbes inside biofilms withstand antibiotic concentrations 100 to 1,000 times higher than their planktonic counterparts, rendering systemic antibiotic infusions ineffective without catheter removal or antimicrobial lock therapy.

---

Evidence-Based CRBSI Prevention Bundles & Lock Therapy

Adherence to standardized, multi-component insertion and maintenance bundles drastically cuts CRBSI rates.

The Central Line Bundle (CDC / SHEA / INS Standards)

1. Maximal Sterile Barrier Precautions: Full-body sterile patient drape, sterile gown, sterile gloves, surgical cap, and mask during catheter insertion.
2. Cutaneous Antisepsis: Skin cleansing with $> 0.5\%$ chlorhexidine gluconate (CHG) in alcohol, using back-and-forth friction (about 30 seconds for common products) and letting it dry completely, per the product label, before puncture. Povidone-iodine needs about 2 minutes to dry.
3. Active Connector Antisepsis ("Scrub the Hub"): Scrub the needleless connector with 70% alcohol or alcoholic CHG, with friction, for the time set by protocol and product (commonly 5 to 15 seconds), then let it dry before accessing the line. Use of continuous passive disinfection caps containing $70\%$ IPA sponges.
4. Site Selection: Subclavian vein preferred over internal jugular in adults; femoral site strictly avoided due to high microbial colonization and thrombosis rates.
5. Daily Assessment of Necessity: Mandatory daily clinical review of line necessity with prompt removal of all non-essential catheters.

Antimicrobial Catheter Lock Therapy (ALT)

When long-term central venous lines (e.g., hemodialysis lines or chemotherapy ports) develop intraluminal CRBSI in stable patients, catheter salvage is attempted using Antimicrobial Catheter Lock Therapy (ALT):

• Principle: Supratherapeutic concentrations of antimicrobials ($100\text{ to }1,000\times\text{MIC}$) usually with an anticoagulant, are instilled to fill the catheter lumen (about $1.5\text{ to }3.0\,\text{mL}$) and left to dwell, alongside systemic antibiotics. IDSA advises renewing the lock at least every 48 hours.
• Standard Lock Regimens:
  • Vancomycin Lock: $2\text{ to }5\,\text{mg/mL}$, alone or with heparin (IDSA-listed combinations use heparin from 10 up to 5,000 units/mL).
  • Gentamicin Lock: $1\text{ to }2\,\text{mg/mL}$ in $0.9\%$ NaCl $+$ Heparin.
  • Ethanol Lock ($70\%$ Ethanol): Non-specific protein denaturant and lipid solvent; highly effective at eradicating both bacterial and fungal biofilms with zero risk of microbial resistance. Requires strict monitoring for polyurethane catheter structural softening and systemic intoxication if accidentally flushed.

---

Post-Infusion Phlebitis: Chemical, Mechanical & Infectious Thresholds

Phlebitis is acute inflammation of the venous tunica intima, manifesting as localized erythema, tenderness, induration, and palpable venous cords.

Classification of Phlebitis

                           [Post-Infusion Phlebitis]
                                      │
         ┌────────────────────────────┼────────────────────────────┐
         ▼                            ▼                            ▼
  [CHEMICAL PHLEBITIS]         [MECHANICAL PHLEBITIS]       [INFECTIOUS PHLEBITIS]
  ├── Osmolarity > 900 mOsm/L  ├── Catheter gauge too large ├── Contamination of insertion
  ├── Extreme pH (< 5 or > 9)  │   relative to vein size    │   site or catheter cannula
  └── Irritating medications   ├── Motion / pistoning       └── Progression to septic
      (Vancomycin, Amiodarone) └── Joint flexion insertion      thrombophlebitis

Chemical Phlebitis: Osmolarity and pH Thresholds

• The Peripheral Osmolarity Threshold ($900\,\text{mOsm/L}$):
  • Solutions exceeding $900\,\text{mOsm/L}$ are strictly contraindicated for peripheral administration and mandate a Central Venous Access Device (CVAD).
  • Peripheral arm veins (cephalic, basilic) have sluggish blood flow rates ($10\text{ to }30\,\text{mL/min}$). Hyperosmolar infusates rapidly draw cellular water out of endothelial cells, precipitating cellular desiccation, endothelial sloughing, basement membrane exposure, and sterile inflammatory thrombosis.
  • The superior vena cava (SVC) has a massive blood flow rate of approximately $2,000\,\text{mL/min}$, achieving instantaneous hemodilution of hypertonic infusions within seconds.
• pH Extremes ($< 5.0$ or $> 9.0$):
  • Normal blood pH is $7.35-7.45$. A pH outside roughly $5\text{ to }9$ is a commonly cited marker of phlebitis risk, although INS guidance now weighs a drug's overall irritant or vesicant properties, not pH alone.
  • Acidic Irritants (pH $< 5.0$): Vancomycin (pH $2.5-4.5$), Amiodarone (pH $3.5-4.5$), Doxycycline, Potassium chloride admixtures.
  • Alkaline Irritants (pH $> 9.0$): Phenytoin (pH $12.0$), Acyclovir (pH $10.5-11.5$), Ampicillin.

Infusion Nurses Society (INS) Phlebitis Grading Scale

---

Loss of Patency: Catheter Occlusion

Loss of patency is one of the adverse events named in the BCSCP outline. The treatment depends on the cause, so identify it first.

Prevention comes from pharmacy work. Check compatibility before co-infusion, keep calcium and phosphate within the solubility curve, filter PN (0.22 µm for 2-in-1, 1.2 µm for TNA), and use flushing protocols such as saline, administer, saline.